GeneDx Holdings Corp
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
WGS$54.83-16.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(in thousands, except share amounts)
| Class A Common Stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income · Total stockholders’ equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Par Value | ||||||
| Balance at December 31, 2022 | 11,773,065 | $1 | $1,378,125 | $(1,124,421) | — | $253,705 |
| Net loss | — | — | — | (175,767) | — | (175,767) |
| Common stock issued pursuant to stock option exercises | 50,444 | — | 285 | — | — | 285 |
| Stock-based compensation expense | — | — | (326) | — | — | (326) |
| Vested restricted stock units converted to common stock | 431,671 | — | — | — | — | — |
| Other comprehensive income, net of tax | — | — | — | — | 425 | 425 |
| Issuance of common stock in registered direct offering, net of issuance costs | 676,868 | — | 7,564 | — | — | 7,564 |
| Issuance of common stock for first Milestone Payment | 701,460 | — | 6,692 | — | — | 6,692 |
| Fractional shares issued upon reverse stock split | 29,603 | — | — | — | — | — |
| Issuance of common stock in underwritten public offering, net of issuance costs | 12,315,752 | 1 | 135,438 | — | — | 135,439 |
| Balance at December 31, 2023 | 25,978,863 | $2 | $1,527,778 | $(1,300,188) | $425 | $228,017 |
| Net loss | — | — | — | (52,286) | — | (52,286) |
| Common stock issued pursuant to stock option exercises | 68,453 | — | 394 | — | — | 394 |
| Common stock issued pursuant to Perceptive warrant exercise | 645,414 | — | 12,586 | — | — | 12,586 |
| Stock-based compensation expense | — | — | 9,138 | — | — | 9,138 |
| Other comprehensive income, net of tax | — | — | — | — | 405 | 405 |
| Vested restricted stock units converted to common stock | 471,663 | — | — | — | — | — |
| Issuance of common stock in ATM offering, net of issuance costs | 825,379 | — | 46,496 | — | — | 46,496 |
| Common stock issued pursuant to employee stock purchase plan | 26,773 | — | 497 | — | — | 497 |
| Balance at December 31, 2024 | 28,016,545 | $2 | $1,596,889 | $(1,352,474) | $830 | $245,247 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.